The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Martin DreylingDuring the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Martin Dreyling, University of Munich, Munich, DE. Martin Dreyling provides an overview of the practice-changing abstracts in mantle cell lymphoma from ASH 2019.
Martin Dreyling talks about treatment strategies for mantle cell lymphoma (MCL). He explains MCL has been subcategorized to conventional indolent type and aggressive MCL, with each receiving a different treatment approach. He also discusses studies that focus on the treatment of MCL in the relapsed setting.
Practice-changing abstracts in MCL from ASH 2019